RNAi therapeutics: a potential new class of pharmaceutical drugs

By D. Bumcrot, M. Manoharan, V. Koteliansky, D. Sah. Nature Chemical Biology, 2006

1,039 citations recorded by the source corpus.

The rapid identification of highly specific and potent drug candidates continues to be a substantial challenge with traditional pharmaceutical approaches. Moreover, many targets have proven to be intractable to traditional small-molecule and protein approaches. Therapeutics based on RNA interference (RNAi) offer a powerful method for rapidly identifying specific and potent inhibitors of disease targets from all molecular classes. Numerous proof-of-concept studies in animal models of human disease demonstrate the broad potential application of RNAi therapeutics. The major challenge for successful drug development is identifying delivery strategies that can be translated to the clinic. With advances in this area and the commencement of multiple clinical trials with RNAi therapeutic candidates, a transformation in modern medicine may soon be realized.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/4c4fe737181225a848fb721052bab8f052781c08

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

siRNA delivery systems for cancer treatment. (2009, background): “Another challenge facing siRNA therapy is ‘immune stimulation’; this is recognition of an siRNA duplex by the innate immune system [13,14].”
siRNA vs. shRNA: similarities and differences. (2009, background): “Introduction of dsRNA longer than 29–30 bp into mammalian cells results in a potent induction of the innate immune system via PKR, similar to the mammalian cell defense mechanism against viral infection [185].”
The origins and evolution of "controlled" drug delivery systems. (2008, background): “, [30]) Nano-scale albumin-based drug carriers have recently reached the clinic.”
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles (2010, background): “1a) containing: (1) a linear, cyclodextrin-based polymer (CDP), (2) a human transferrin protein (TF) targeting ligand displayed on the exterior of the nanoparticle to engage TF receptors (TFR) on the surface of the cancer cells, (3) a hydrophilic polymer (polyethylene glycol (PEG) used to promote na”
Interfering with disease: a progress report on siRNA-based therapeutics (2007, background): “Numerous publications have reported successful antitumoural effects following either direct or systemic tumoural injection of lipid-formulated siRNA (for reviews see REFS 33, 38, 39) .”
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. (2013, background): “The use of siRNAs to specifically silence genes involved in disease pathogenesis holds promise for the development of a new and far-reaching class of therapeutics (3, 4).”
Catalytic in vivo protein knockdown by small-molecule PROTACs (2015, positive): “We designed PROTAC_RIPK2 (3) by making use of a previously reported cell-active inhibitor (Fig.”